Want to see HK:1609 full AI Analyst Report?
Top Page
Star Sports Medicine Co., Ltd Class H
(1609)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$82.00
Action:Reiterated
Date:10/01/26
The score is primarily supported by strong financial performance (high margins, rapid revenue scaling, low leverage, and solid free cash flow). It is held back by very weak technicals indicating a pronounced downtrend, and a premium valuation (P/E ~37.6) without a provided dividend yield to offset it.
Positive Factors
Revenue Scaling
The sharp multi-year expansion shows that the company has moved beyond its early scale and is continuing to grow materially. Sustained 2025 growth supports broader market adoption, creates operating leverage, and provides a stronger base for future earnings generation.
Negative Factors
Historical Earnings Volatility
The earlier loss-making period shows that profitability has not always been durable through the company’s development and scaling process. Although recent results are stronger, this history indicates execution and scale-up risk if growth slows or operating conditions become less favorable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scaling
The sharp multi-year expansion shows that the company has moved beyond its early scale and is continuing to grow materially. Sustained 2025 growth supports broader market adoption, creates operating leverage, and provides a stronger base for future earnings generation.
Read all positive factors
Star Sports Medicine Co., Ltd Class H (1609) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.38B
Dividend YieldN/A
Average Volume (3M)419.41K
Price to Earnings (P/E)39.7
Beta (1Y)0.97
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees384
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,831,345
10 Day Avg. Volume379,990
30 Day Avg. Volume419,407
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)7.96
Price to Sales (P/S)12.04
P/FCF Ratio39.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Star Sports Medicine Co., Ltd Class H Business Overview & Revenue Model
Company Description
Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carb...
Star Sports Medicine Co., Ltd Class H Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 402.75M | 327.12M | 238.54M | 146.60M | 89.58M |
| Gross Profit | 298.62M | 227.59M | 177.31M | 103.94M | 59.68M |
| EBITDA | 169.36M | 121.86M | 77.68M | 48.33M | -141.29M |
| Net Income | 136.97M | 95.39M | 57.11M | 40.34M | -135.26M |
Balance Sheet | |||||
| Total Assets | 764.08M | 617.33M | 451.28M | 346.92M | 347.22M |
| Cash, Cash Equivalents and Short-Term Investments | 539.78M | 434.06M | 356.37M | 272.84M | 263.70M |
| Total Debt | 32.62M | 22.58M | 8.33M | 11.06M | 12.46M |
| Total Liabilities | 154.66M | 146.09M | 76.51M | 18.69M | 60.58M |
| Stockholders Equity | 609.42M | 471.24M | 374.77M | 328.24M | 286.63M |
Cash Flow | |||||
| Free Cash Flow | 122.88M | 67.36M | 58.60M | 47.30M | 5.96M |
| Operating Cash Flow | 157.12M | 94.52M | 79.86M | 55.81M | 9.82M |
| Investing Cash Flow | -120.56M | -371.25M | -21.17M | 6.03M | 1.54M |
| Financing Cash Flow | -9.35M | 10.13M | 24.59M | 133.36M | 58.27M |
Star Sports Medicine Co., Ltd Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$4.38B | 39.71 | 15.57% | ― | ― | ― | |
67 Neutral | HK$2.32B | 5.65 | 28.73% | 7.27% | -2.76% | -7.88% | |
67 Neutral | HK$281.27M | 10.99 | 11.30% | 2.53% | 86.04% | 118.12% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | HK$433.73M | 36.54 | 3.68% | 7.94% | 4.28% | 25.30% | |
49 Neutral | HK$13.39B | -310.10 | -19.61% | ― | -25.67% | -1034.21% | |
48 Neutral | HK$2.80B | -38.46 | -42.47% | ― | 33.88% | -735.09% |
* General Sector Average
HK:1609
Star Sports Medicine Co., Ltd Class H
79.80
-135.20
-62.88%
HK:9929
SEM Holdings Limited
1.40
1.33
1900.00%
HK:2262
Steve Leung Design Group Limited
0.38
-0.66
-63.46%
HK:0331
FSE Lifestyle Services Limited
5.15
-0.20
-3.69%
HK:3928
S&T Holdings Ltd.
27.00
22.34
479.40%
HK:8629
Guangdong Syntrust GK Testing and Certification Tech Service Center Co., Ltd. Class H
8.29
0.28
3.44%
Star Sports Medicine Co., Ltd Class H Corporate Events
Star Sports Medicine Calls EGM to Approve 2026 Share Incentive Scheme
Sep 30, 2026
Star Sports Medicine Co., Ltd. has called a second extraordinary shareholders’ meeting for October 22, 2026, in Beijing, open to eligible H-shareholders recorded on the register by the specified cut-off date. Shareholders may vote in person ...
Star Sports Medicine Wins EU MDR and Overseas Device Approvals
Sep 10, 2026
Star Sports Medicine Co., Ltd is a China-based sports medicine manufacturer focused on medical devices and surgical instruments for joint repair and arthroscopic procedures. Its portfolio spans implants, active devices, consumables and endoscopic ...
Star Sports Medicine Launches Authorized H-Share Buyback Plan
Aug 18, 2026
Star Sports Medicine Co., Ltd. has received shareholder approval at its 2025 annual meeting for a general mandate allowing the board to repurchase up to 10% of its issued H shares, with an initial plan to buy back up to about 2.90 million shares, ...
Star Sports Medicine Boosts Revenue but Sees Interim Profit Decline on Higher Costs
Aug 17, 2026
Star Sports Medicine Co., Ltd reported a 21.6% year-on-year increase in revenue to RMB163.4 million for the six months ended 30 June 2026, driven by strong gross profit growth of 21.8% to RMB121.3 million, underscoring solid topline momentum in it...
Star Sports Medicine Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 5, 2026
Star Sports Medicine Co., Ltd. has called a board meeting for August 17, 2026, to review and approve its interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recommend ...
Star Sports Medicine unveils 2026 share incentive scheme to align talent and investors
Aug 3, 2026
Star Sports Medicine Co., Ltd. plans to adopt a 2026 share incentive scheme, subject to shareholder approval at an upcoming meeting, to strengthen its long-term incentive mechanisms. The scheme uses a trust structure to acquire H shares from the m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.